how to change from semaglutide to tirzepatide Switching Switching GLP-1 Agonists for MAXIMUM
Description
A 2025 systematic review mapped weight change after stopping anti-obesity medicines across 11 RCTs
Each person responds differently based on their metabolism, physical activity levels, and how well they follow dietary recommendations
Lost a pound this week
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
a priority setting partnership between patients and healthcare professionals
Both offer unique benefits for weight loss, but understanding their differences is key to choosing the right treatment
